文献速递中毒与环境急症心脑血管急症重症综合管理与镇静镇痛

吡哆醇/吡哆醛-5'-磷酸补充改善酒精戒断综合征结局并促进长期戒断:一个假说

Pyridoxine/pyridoxal-5'-phosphate repletion to improve outcomes of alcohol withdrawal syndrome and promote long-term abstinence: a hypothesis.
PubMed 文献 · Clin Toxicol (Phila) · 2026-07-21
一句话结论酒精使用障碍患者普遍缺乏吡哆醛-5'-磷酸,补充吡哆醇可能减轻戒断严重程度、改善难治性戒断并减少渴求,但尚需研究验证。

本文为假说性文章,提出酒精使用障碍患者因乙醛置换结合蛋白、肝病增加磷酸酶活性等机制普遍缺乏吡哆醛-5'-磷酸(维生素B6活性形式)。缺乏该辅酶会损害谷氨酸脱羧酶将谷氨酸转化为GABA,加剧谷氨酸能/GABA能失衡,从而可能加重酒精戒断症状、降低惊厥阈值、诱发难治性癫痫发作并增加渴求。文中引用小型研究:接受丙嗪戒断治疗者补充吡哆醇120 mg/日较20 mg/日癫痫发作更少(P=0.02);发生戒断癫痫后进展为震颤谵妄者吡哆醛-5'-磷酸浓度更低(P=0.011)。作者结论为酒精使用障碍中补充吡哆醛-5'-磷酸值得研究。

要点

  • 酒精使用障碍患者普遍缺乏吡哆醛-5'-磷酸,但临床不像硫胺素那样常规补充。
  • 缺乏吡哆醛-5'-磷酸损害谷氨酸脱羧酶功能,加剧谷氨酸/GABA失衡,可能加重戒断并降低惊厥阈值。
  • 小型研究:丙嗪戒断治疗者吡哆醇120 mg/日较20 mg/日癫痫发作更少(P=0.02)。
  • 发生戒断癫痫后进展为震颤谵妄者吡哆醛-5'-磷酸浓度更低(P=0.011)。
  • 其他原因(营养性吡哆醇不足、异烟肼中毒、先天代谢病)所致吡哆醛-5'-磷酸缺乏的癫痫对苯二氮䓬类和苯巴比妥难治,补充吡哆醇后可控制,提示难治性戒断可能对吡哆醇有反应。

适用人群与场景

  • 酒精使用障碍患者,包括接受酒精戒断治疗者及戒断后维持戒断者。
  • 原文未明确排除人群。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文提及在丙嗪戒断治疗的患者中补充吡哆醇120 mg/日较20 mg/日癫痫发作更少(P=0.02),但未说明给药途径和疗程,也未作为推荐剂量。
  • 原文提出静脉吡哆醇用于治疗营养性吡哆醇不足、异烟肼中毒和先天代谢病所致吡哆醛-5'-磷酸缺乏的癫痫有效且安全,但未给出具体剂量、途径和疗程。
  • 原文未提及酒精戒断综合征中补充吡哆醇的具体给药方案。

红旗征与不能漏的情况

  • 酒精戒断癫痫:吡哆醇缺乏者癫痫发作更常见,且对苯二氮䓬类和苯巴比妥可能难治,直至给予吡哆醇。
  • 震颤谵妄:发生戒断癫痫后进展为震颤谵妄者吡哆醛-5'-磷酸浓度更低(P=0.011)。
  • 焦虑、困惑:酒精戒断和吡哆醛-5'-磷酸缺乏均可引起,二者叠加时症状可能加重。

研究设计与关键结果

  • 本文为假说性文章,未开展原始研究。
  • 引用小型研究:酒精使用障碍者中吡哆醇缺乏在发生戒断癫痫者中更常见。
  • 引用研究:丙嗪戒断治疗者吡哆醇120 mg/日较20 mg/日癫痫发作更少(P=0.02)。
  • 引用研究:戒断癫痫后进展为震颤谵妄者吡哆醛-5'-磷酸浓度低于未进展者(P=0.011)。

证据类型、等级与局限

  • 证据类型:假说性文章,基于机制推理和引用的小型研究及动物模型。
  • 局限:主要为假说,引用研究样本小,部分治疗(丙嗪)已过时,需前瞻性研究验证。

对床旁实践的改变

  • 提示急诊/ICU医生在酒精戒断综合征患者中应关注吡哆醛-5'-磷酸缺乏,尤其难治性癫痫发作者,但原文未给出补充吡哆醇的推荐剂量和途径,不能据此改变常规实践。
  • 原文未提及适用与不适用人群的具体标准。
  • 常见陷阱:不能将原文中丙嗪戒断治疗下的吡哆醇120 mg/日 vs 20 mg/日的研究方案剂量当作通用推荐剂量。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: Deficiency of pyridoxal-5'-phosphate, the clinically measured and active form of pyridoxine (vitamin B6), is prevalent among those with alcohol use disorder. However, unlike thiamine, pyridoxal-5'-phosphate is not routinely repleted. Evidence is presented that its repletion would improve outcomes of alcohol withdrawal syndrome and promote long-term abstinence.

PYRIDOXAL-5′-PHOSPHATE DEFICIENCY CAN CAUSE A CLINICALLY CONSEQUENTIAL GLUTAMATERGIC/GABAERGIC SIGNALING IMBALANCE: Excessive excitatory glutamatergic signaling and inadequate inhibitory GABAergic signaling are central to the pathophysiology of alcohol withdrawal syndrome. Pyridoxal-5'-phosphate is an essential cofactor for the rate-limiting enzyme in the conversion of glutamate to GABA, glutamic acid decarboxylase. Therefore, pyridoxal-5'-phosphate deficiency would be expected to exacerbate the signaling imbalance that underlies alcohol withdrawal syndrome, worsening symptoms and treatment response. This is supported by the finding that pyridoxal-5'-phosphate deficiency-whether in animal models or other clinical conditions, including nutritional pyridoxine insufficiency, isoniazid toxicity, and certain inborn errors of metabolism-can create a glutamatergic/GABAergic imbalance severe enough to cause anticonvulsant-refractory status epilepticus.

MECHANISMS OF PYRIDOXAL-5′-PHOSPHATE DEFICIENCY IN ALCOHOL USE DISORDER: Pyridoxal-5'-phosphate deficiency in alcohol use disorder occurs in part because alcohol is oxidized by alcohol dehydrogenase to acetaldehyde, which displaces pyridoxal-5'-phosphate from binding proteins, exposing it to hydrolysis by phosphatases. Hepatic disease promotes deficiency through increased phosphatase activity. Other mechanisms, including poor nutritional intake, likely contribute.

PYRIDOXAL-5′-PHOSPHATE DEFICIENCY MAY SURREPTITIOUSLY PRECIPITATE OR EXACERBATE CLINICAL MANIFESTATIONS OF ALCOHOL WITHDRAWAL: In a small study of individuals with alcohol use disorder, pyridoxine deficiency was more prevalent in those who had an alcohol withdrawal seizure than in those who had not. More notably, among patients treated for alcohol withdrawal with the phenothiazine promazine-an obsolete treatment now known to lower the seizure threshold in alcohol withdrawal-supplementation with pyridoxine 120 mg/day resulted in fewer seizures than pyridoxine 20 mg/day (P = 0.02). These findings are consistent with animal models in which pyridoxal-5'-phosphate deficiency lowers the seizure threshold. In another study, of patients who suffered alcohol withdrawal seizures, those who progressed to delirium tremens had lower pyridoxal-5'-phosphate concentrations than those who did not (P = 0.011). Finally, anxiety and confusion are manifestations of both alcohol withdrawal and pyridoxal-5'-phosphate deficiency, presumably in part due to the signaling imbalance common to both. Therefore, these symptoms may be compounded when alcohol withdrawal is superimposed on pyridoxal-5'-phosphate deficiency.

TREATMENT OF PYRIDOXAL-5′-PHOSPHATE DEFICIENCY IN ALCOHOL WITHDRAWAL SYNDROME: The established effectiveness and safety of intravenous pyridoxine in treating seizures and other symptoms resulting from pyridoxal-5'-phosphate deficiency caused by nutritional pyridoxine insufficiency, isoniazid toxicity, and inborn errors of metabolism provide proof of concept that pyridoxine supplementation may safely reduce the severity of alcohol withdrawal syndrome and enhance the response to treatment of those who are deficient. Indeed, seizures resulting from these other causes of pyridoxal-5'-phosphate deficiency remain refractory to benzodiazepines and phenobarbital until administration of pyridoxine, suggesting that some patients with treatment-refractory alcohol withdrawal syndrome would become treatment-responsive after pyridoxine treatment.

PYRIDOXAL-5′-PHOSPHATE DEFICIENCY MAY INCREASE ALCOHOL CRAVING: In addition to causing a glutamate/GABA imbalance, pyridoxal-5'-phosphate deficiency may decrease CNS serotonin through inhibition of aromatic L-amino acid decarboxylase. Both effects can cause anxiety, stress sensitivity, and dysphoria, contributing to craving. Repletion may attenuate these symptoms and, thereby, reduce craving.

DISCUSSION: Pyridoxal-5'-phosphate deficiency produces an excitatory/inhibitory imbalance by impairing the conversion of glutamate to GABA-an imbalance that in other clinical contexts can manifest as anticonvulsant-refractory seizures. It is therefore unlikely that pyridoxal-5'-phosphate deficiency always remains clinically silent during alcohol withdrawal. Moreover, during non-withdrawal abstinence, pyridoxal-5'-phosphate deficiency may cause a glutamate/GABA imbalance and low serotonin, possibly triggering anxiety, stress sensitivity, and dysphoria, thereby increasing craving.

CONCLUSION: Pyridoxal-5'-phosphate repletion in alcohol use disorder warrants investigation.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Weintraub SJ. Pyridoxine/pyridoxal-5'-phosphate repletion to improve outcomes of alcohol withdrawal syndrome and promote long-term abstinence: a hypothesis. Clin Toxicol (Phila). 2026. PMID: 42480097. doi:10.1080/15563650.2026.2702501

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。